Study M687
Study name | Zhou XJ 2020a |
Title | Anti-depressive effects of Kai-Xin-San on lipid metabolism in depressed patients and CUMS rats using metabolomic analysis |
Overall design | The aim of this study was to assess the effects of Kai-Xin-San (KXS) on lipid metabolism in depressed patients. Patients with depressed patients were divided into two groups: (1) Kai-Xin-San group (Kai-Xin-San 13.336 g/day plus fluoxetine placebo), and (2) fluoxetine group (fluoxetine 20 mg/day plus Kai-Xin-San placebo). Patients were treated for 8 weeks. Healthy controls (control group) were also recruited. Serum lipid metabolomics were analyzed by UPLC-Q-TOF/MS technology, and differential metabolites were validated in a large sample size (control group, n = 23; depression group, n = 20; Kai-Xin-San group, n = 24). |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed depressive disorder, HAMD-17 scores of 17 to 24 |
Sample size | 77 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: Agilent 1100 quaternary high-performance liquid chromatography (Agilent, EASY-nLC 1000, USA) with Q-Exactive mass spectrometer (Thermo Finnigan, Germany); |
PMID | |
DOI | |
Citation | Zhou X, Wang J, Lu Y, et al. Anti-depressive effects of Kai-Xin-San on lipid metabolism in depressed patients and CUMS rats using metabolomic analysis. J Ethnopharmacol. 2020;252:112615. |
Metabolite | PC(O-36:4); 3-(3-Hydroxyphenyl)propanoic acid; DG(18:1(9Z)/18:2(9Z,12Z)/0:0); SM(d18:1/18:0); Cer(d18:1/16:0); LysoPC(20:4/0:0); PE(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0); LysoPC(20:2(11Z,14Z)/0:0); PC(18:0/20:4(5Z,8Z,11Z,14Z)); PC(16:0/P-18:0); PC(16:0/P-18:1(11Z)); LysoPI(16:0/0:0); LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)); LysoPC(22:5(4Z,7Z,10Z,13Z,16Z)/0:0); PE(P-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); SM(d18:1/18:1(11Z)); PE(20:4(5Z,8Z,11Z,14Z)/16:0); PE(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z)); PE(P-16:0/20:4(5Z,8Z,11Z,14Z)); PC(18:0/18:1(11Z)); PC(15:0/20:4(5Z,8Z,11Z,14Z)); Hydroxyclomipramine; PC(18:0/14:0); PC(18:0/20:3(5Z,8Z,11Z)); LysoPI(0:0/18:0); SM(d18:0/18:1(11Z)); N-Desmethylcitalopram; LysoPE(0:0/22:2(13Z,16Z)); PC(14:1(9Z)/24:0); PC(o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); PC(18:2(9Z,12Z)/20:0); PC(P-18:1(11Z)/20:0); PC(o-18:0/20:4(8Z,11Z,14Z,17Z)); PC(18:0/20:2(11Z,14Z)); PE(20:1(11Z)/18:0); PC(O-16:0/20:3(8Z,11Z,14Z)); PC(18:0/16:0); PC(18:1(11Z)/18:0); PGP(16:0/18:0); SM(d18:1/24:1(15Z)); Cholesteryl acetate; PC(14:0/18:0); SM(d18:1/20:0); SM(d18:1/22:1(13Z)); 7alpha-Hydroxy-3-oxo-4-cholestenoate; PC(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)); Gentamicin; 1-Phenyl-1,3-heptadecanedione; 3-keto Fusidic acid; PC(P-18:0/20:3(5Z,8Z,11Z)); Glycerol 1,3-ditetradecanoate 2-(9Z-octadecenoate); PGP(18:1(11Z)/18:1(9Z)); PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0); PC(o-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0); |
